GH (GH)
Quantitative Summary
DeterministicFinancial health is average: Piotroski 5/9, Altman Z 1.3.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe fundamental economics reveal a stark divergence between top-line expansion and bottom-line destruction, characterized by a -19.1% ROIC that underscores severe capital inefficiency despite robust 32.9% revenue growth. The DuPont decomposition highlights an anomalous structure where extreme leverage (-20.28x equity multiplier) and negative net margins (-42.4%) are mathematically offsetting to produce a reported ROE of 419.2%; however, this metric is misleading given the gross margin contraction relative to expenses. While the Piotroski F-Score of 5/9 indicates moderate financial stability with no major deteriorations in quality metrics recently, the Beneish M-Score of -2.70 suggests low earnings manipulation risk yet fails to account for the persistent profitability erosion evident in the negative net income.
Valuation analysis requires caution due to the lack of positive earnings denominators; consequently, traditional P/E comparisons are non-functional, forcing an assessment based on growth-at-a-reasonable-price dynamics rather than multiple compression or expansion. The market appears pricing in aggressive future normalization, as current valuations do not reflect the historical reality of sustained losses. While the Fama-French alpha of 48.06% signals significant outperformance relative to a factor model over the annual period, this return is heavily skewed by the value and profitability factors, which register -0.289 and -1.249 respectively, indicating the stock behaves more like a high-growth speculative asset than a value compounder despite its sector-agnostic classification.
Risk assessment points to concentrated downside pressure driven primarily by insider activity, with $6,325,605 in net selling over the last 90 days suggesting internal skepticism regarding future cash flow generation or valuation levels. The combination of weak profitability (RMW) and a growth tilt creates an asymmetric risk profile where upside depends entirely on margin recovery while downside exposure remains anchored by the current burn rate and high leverage. Investors must weigh whether the revenue acceleration can sustainably convert into positive operating margins before any meaningful equity value appreciation occurs, noting that the current factor exposures do not support a traditional defensive or value-oriented thesis.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
Price Chart with Moving Averages
Technical Setup
AI GeneratedThe current trading price of $114.97 for GH sits within a specific technical context that requires further data points regarding its moving averages to fully define the trend status, as no explicit MA values were provided in the input. Without knowing whether this level is positioned above or below key short-term or long-term averages like the 50-day or 200-day lines, it remains impossible to determine if the asset is technically bullish or bearish based solely on price location relative to these benchmarks. The absence of Relative Strength Index data also leaves a critical gap in assessing immediate momentum; typically, an RSI above 70 would signal potential overbought conditions while readings below 30 might indicate oversold states, but without this metric, the short-term velocity cannot be characterized as strong or weak. Consequently, the technical picture remains incomplete regarding directional bias and momentum strength. While the price level is established at $114.97, confirming whether this represents a breakout above resistance or a consolidation below support requires additional information on average alignment. Similarly, distinguishing between healthy upward movement and exhausted gains depends entirely on oscillator readings that are currently missing from the dataset. Any conclusion about market direction would be speculative without these essential comparative metrics against historical price averages and momentum oscillators.
Quant Health Deep Dive
Profitability & Value Creation
DuPont Analysis — ROE Decomposition
Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.
Balance Sheet Health
Insider Activity (Last 90 Days)
Open-market buys vs sells by company insiders. Source: yfinance.
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Risk Profile
Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fama-French 5-Factor Exposure
Academic factor model decomposition — what's really driving this stock's returns.
Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like ARKG or XHS, the fund manager is mechanically forced to buy or sell GH shares regardless of GH's individual fundamentals. We estimate $616M of passive capital is structurally linked to GH through 8 tracked ETFs. Passive flows have a limited but growing influence on GH's daily trading dynamics.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in GH to visualize passive redemption contagion across ETFs and collateral stocks.
If GH (GH) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies TWIST BIOSCIENCE CORP (TWST) as the most exposed collateral stock, sharing 1 ETFs with GH. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 9 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
GH Ownership Dynamics
Passive funds hold 1 in every 18 GH shares, reducing daily market volatility.
GH (GH) exerts measurable gravity on the passive index market, currently representing 4.7% of the ARK Genomic Revolution ETF (ARKG) and 2.4% of the XHS (XHS). Across 9 tracked ETFs, approximately 7M shares (5.6% of float) are held by passive funds and rarely trade on the open market. As passive ownership grows, index inclusion changes may increasingly drive price discovery.
ETFs with Highest GH Exposure
Float lock-up computed from 9 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
GH Institutional Volume Profile
252-day volume distribution by price level. The Point of Control (POC) marks — the price where the most institutional volume transacted — an implicit support/resistance floor.
The highest-volume price zone for GH over the past year sits near $60.91 (10% of 252-day volume). The current price of $130.17 trades 113.7% above this institutional floor — a sign of upside momentum, though a pullback to the POC zone is a common reversion target.
Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-14 | 5 | $98.47 | $492.35 |
| 2026-05-13 | 65,529 | $99.94 | $6.5M |
| 2026-05-12 | 5 | $96.71 | $483.55 |
| 2026-04-27 | 672 | $88.91 | $59,747.52 |
| 2026-04-24 | 25,922 | $87.87 | $2.3M |
| 2026-04-23 | 55,094 | $89.56 | $4.9M |
| 2026-04-22 | 12,999 | $90.36 | $1.2M |
| 2026-04-21 | 3,028 | $91.07 | $275,759.96 |
| 2026-04-20 | 482 | $90.36 | $43,553.52 |
| 2026-04-17 | 1,252 | $85.70 | $107,296.4 |
| 2026-04-15 | 28 | $86.40 | $2,419.2 |
| 2026-04-10 | 9,976 | $87.17 | $869,607.92 |
| 2026-04-09 | 1,464 | $92.84 | $135,917.76 |
| 2026-04-06 | 10,608 | $93.83 | $995,348.64 |
| 2026-03-25 | 11 | $83.59 | $919.49 |
| 2026-03-16 | 6,737 | $85.49 | $575,946.13 |
| 2026-03-11 | 92 | $90.49 | $8,325.08 |
| 2026-03-06 | 440 | $92.58 | $40,735.2 |
| 2026-03-03 | 648 | $92.23 | $59,765.04 |
| 2026-02-27 | 4,569 | $97.97 | $447,624.93 |
| 2026-02-24 | 201 | $94.42 | $18,978.42 |
| 2026-02-18 | 790 | $107.11 | $84,616.9 |
| 2026-02-13 | 30 | $102.76 | $3,082.8 |
| 2026-02-12 | 100 | $107.58 | $10,758 |
| 2026-02-10 | 5 | $105.34 | $526.7 |
| 2026-02-03 | 120 | $114.90 | $13,788 |
| 2026-02-02 | 157 | $114.04 | $17,904.28 |
| 2026-01-30 | 20 | $110.48 | $2,209.6 |
| 2026-01-20 | 4,400 | $112.14 | $493,416 |
| 2026-01-16 | 7,218 | $111.98 | $808,271.64 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Price Correlations
Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.
| Peer | 252-Day (1Y) | 126-Day (6M) | Direction |
|---|---|---|---|
| WTGXX | NaN | NaN | |
| NTRA | 0.481 | 0.487 | Moderate |
| VIAV | 0.339 | 0.345 | Moderate |
| VCYT | 0.335 | 0.268 | Moderate |
| TEM | 0.325 | 0.317 | Moderate |
| PSNL | 0.325 | 0.365 | Moderate |
| GSAT | 0.322 | 0.369 | Moderate |
| CHRW | 0.319 | 0.552 | Moderate |
| CAH | 0.319 | 0.459 | Moderate |
| ALGN | 0.317 | 0.281 | Moderate |
Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.
Compare GH to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-02.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.